Know Cancer

or
forgot password

A Randomized, Open-label Study Comparing the Anti-tumor Effect of Treatment With Tarceva Plus Avastin Versus Chemotherapy Plus Avastin in Patients With Advanced Non-small Cell Lung Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Non-Small Cell Lung Cancer

Thank you

Trial Information

A Randomized, Open-label Study Comparing the Anti-tumor Effect of Treatment With Tarceva Plus Avastin Versus Chemotherapy Plus Avastin in Patients With Advanced Non-small Cell Lung Cancer


Inclusion Criteria:



- adult patients, >=18 years of age;

- advanced (stage IIIb and IV) non-small cell lung cancer;

- measurable disease;

- ECOG PS 0-1.

Exclusion Criteria:

- prior chemotherapy or treatment with another systemic anti-cancer agent;

- radiotherapy within 4 weeks prior to first dose of study treatment;

- CNS metastases;

- other malignancies in past 5 years, except for adequately treated cancer in situ of
the cervix, basal or squamous cell skin cancer.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-free survival

Outcome Time Frame:

Event driven

Safety Issue:

No

Principal Investigator

Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

Hoffmann-La Roche

Authority:

Belgium: Federal Agency for Medicines and Health

Study ID:

BO20571

NCT ID:

NCT00531960

Start Date:

January 2008

Completion Date:

January 2010

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location